Publications
371
Citations
10,028
Est. group size
~43
Recurring co-author estimate
Active years
50
Publishing since 1977
Mitch A. Phelps works in clinical pharmacology and oncology, focusing on how drugs behave in the body (pharmacokinetics) and how that information can be used to personalize cancer treatment dosing, particularly for blood cancers like multiple myeloma and leukemia. His work spans early-phase clinical trials, drug modeling (including physiologically based pharmacokinetic models), and studies on immunotherapies and targeted cancer treatments.
Publication output has grown substantially over the last decade, with a marked increase in output during 2023 and 2025 compared to earlier years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Development of a Pregnancy‐Specific Physiologically Based Pharmacokinetics (PBPK) Model for Aspirin
CPT Pharmacometrics & Systems Pharmacology · 2026
- Abstract 2992: The role of FOXD1 in the anaplastic transformation of thyroid cancer
Cancer Research · 2026
- Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
Transplantation and Cellular Therapy · 2025
- 1106 Assessing Weight Changes Post-Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Adults at a Federally Qualified Health Center
Journal of the American Pharmacists Association · 2025
- 689 The mTORC1/2 dual inhibitor AZD2014 enhances inotuzumab ozogamicin-induced apoptosis in B-cell non-hodgkin lymphoma cells via lysosomal function activation
Regular and Young Investigator Award Abstracts · 2025
- Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Breast Cancer Research and Treatment · 2024
- Mymel: A Phase 1 Trial of AUC-Targeted High Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Transplant
Transplantation and Cellular Therapy · 2024
- 8.3 – 00088 Epitope-Driven Effector Functions of Broadly Neutralizing Antibodies Across Diverse HIV Isolates: Insights for Next-Generation Therapeutics
Journal of Virus Eradication · 2024
- Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab
Clinical Pharmacokinetics · 2023
- RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity
Biomaterials · 2023
- Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
The Oncologist · 2023
- Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma
Cancers · 2023
- An Exploratory Analysis on the Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Received BCMA CAR-T Therapy in the Cartitude-1 Study
Transplantation and Cellular Therapy · 2023
- Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)
Transplantation and Cellular Therapy · 2023
- Supplementary Figures 1-7, Tables 1-2 from miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival
2023
- Blood×15
- Regular and Young Investigator Award Abstracts×9
- Journal of Clinical Oncology×6
- Cancer Research×6
- Leukemia & lymphoma/Leukemia and lymphoma×5
- Tzyy-Jye Doong
Medicine · The Ohio State University
- Daniel Jones
Medicine · The Ohio State University
- James S. Blachly
Medicine · The Ohio State University
- Michael R. Grever
Medicine · The Ohio State University
- Charles T. Gregory
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile